{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T09:57:00Z","timestamp":1777888620196,"version":"3.51.4"},"reference-count":38,"publisher":"SAGE Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPD"],"published-print":{"date-parts":[[2022,5,24]]},"abstract":"<jats:p>Background: Drug therapy is important for controlling symptoms in Parkinson\u2019s disease (PD). However, it often results in complex medication regimens and could easily lead to drug related problems (DRP), suboptimal adherence and reduced treatment efficacy. A structured medication review (SMR) could address these issues and optimize therapy, although little is known about clinical effects in PD patients. Objective: To analyze whether an SMR improves quality of life (QoL) in PD. Methods: In this multicenter randomized controlled trial, half of the 202 PD patients with polypharmacy received a community pharmacist-led SMR. The control group received usual care. Assessments at baseline, and after three and six months comprised six validated questionnaires. Primary outcome was PD specific QoL [(PDQ-39; range 0 (best QoL) \u2013 100 (worst QoL)]. Secondary outcomes were disability score, non-motor symptoms, general health status, and personal care giver\u2019s QoL. Furthermore, DRPs, proposed interventions, and implemented modifications in medication schedules were analyzed. Results: No improvement in QoL was seen six months after an SMR, with a non-significant treatment effect difference of 2.09 (\u20130.63;4.80) in favor of the control group. No differences were found in secondary outcomes. In total, 260 potential DRPs were identified (2.6 (\u00b11.8) per patient), of which 62% led to drug therapy optimization. Conclusion: In the current setting, a community pharmacist-led SMR did not improve QoL in PD patients, nor improved other pre-specified outcomes.<\/jats:p>","DOI":"10.3233\/jpd-213021","type":"journal-article","created":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T13:56:12Z","timestamp":1646402172000},"page":"1295-1306","source":"Crossref","is-referenced-by-count":6,"title":["The Effect of a Structured Medication Review on Quality of Life in Parkinson\u2019s Disease"],"prefix":"10.1177","volume":"12","author":[{"given":"Nicol G.M.","family":"Oonk","sequence":"first","affiliation":[{"name":"Department of Neurology, Medisch Spectrum Twente, Enschede, the Netherlands"},{"name":"Section Cognition, Data and Education, University of Twente, Enschede, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kris L.L.","family":"Movig","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Medisch Spectrum Twente, Enschede, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Job","family":"van der Palen","sequence":"additional","affiliation":[{"name":"Section Cognition, Data and Education, University of Twente, Enschede, the Netherlands"},{"name":"Department of Epidemiology, Medisch Spectrum Twente, Enschede, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone A.F.","family":"Nibourg","sequence":"additional","affiliation":[{"name":"Department of Neurology, Isala klinieken, Zwolle, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten","family":"Koehorst-ter Huurne","sequence":"additional","affiliation":[{"name":"Pharmacy De Hofbraak, Haaksbergen, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henk-Willem","family":"Nijmeijer","sequence":"additional","affiliation":[{"name":"Department of Neurology, Ziekenhuis Groep Twente, Almelo, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirjam E.","family":"van Kesteren","sequence":"additional","affiliation":[{"name":"Department of Neurology, Isala klinieken, Zwolle, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucille D.A.","family":"Dorresteijn","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medisch Spectrum Twente, Enschede, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/JPD-213021_ref1","first-page":"CD006564","article-title":"Dopamine agonist therapy in early Parkinson\u2019s disease","author":"Stowe","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.3233\/JPD-213021_ref2","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/mds.27372","article-title":"International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson\u2019s disease","volume":"33","author":"Fox","year":"2018","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-213021_ref3","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12883-017-0904-4","article-title":"Co-morbidity and polypharmacy in Parkinson\u2019s disease: Insights from a large Scottish primary care database","volume":"17","author":"McLean","year":"2017","journal-title":"BMC Neurol"},{"key":"10.3233\/JPD-213021_ref4","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/mds.20041","article-title":"Drug adherence in Parkinson\u2019s disease","volume":"19","author":"Leopold","year":"2004","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-213021_ref5","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/mds.20602","article-title":"Suboptimal medication adherence in Parkinson\u2019s disease","volume":"20","author":"Grosset","year":"2005","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-213021_ref6","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/mds.21831","article-title":"Medication adherence and associated outcomes in medicare health maintenance organization-enrolled older adults with Parkinson\u2019s disease","volume":"23","author":"Kulkarni","year":"2008","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-213021_ref7","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/mds.22112","article-title":"Adherence to antiparkinson medication in a multicenter European study","volume":"24","author":"Grosset","year":"2009","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-213021_ref8","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/mds.22999","article-title":"Prevalence and cost of medication nonadherence in Parkinson\u2019s disease: Evidence from administrative claims data","volume":"25","author":"Davis","year":"2010","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-213021_ref9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s40263-014-0220-0","article-title":"Medication adherence in patients with Parkinson\u2019s disease","author":"Malek","year":"2015","journal-title":"CNS Drugs"},{"key":"10.3233\/JPD-213021_ref10","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s11096-011-9526-x","article-title":"Drug-related problems in Parkinson\u2019s disease: The role of community pharmacists in primary care","volume":"33","author":"Schr\u00f6der","year":"2011","journal-title":"Int J Clin Pharm"},{"key":"10.3233\/JPD-213021_ref11","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.parkreldis.2012.09.004","article-title":"Systematic review on factors associated with medication non-adherence in Parkinson\u2019s disease","volume":"18","author":"Daley","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-213021_ref13","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.sapharm.2016.08.005","article-title":"Pharmacist-led medication review in community settings: An overview of systematic reviews","volume":"13","author":"Jokanovic","year":"2017","journal-title":"Res Soc Adm Pharm"},{"key":"10.3233\/JPD-213021_ref14","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s11096-014-9947-4","article-title":"Large scale implementation of clinical medication reviews in Dutch community pharmacies: Drug-related problems and interventions","volume":"36","author":"Kempen","year":"2014","journal-title":"Int J Clin Pharm"},{"key":"10.3233\/JPD-213021_ref15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2165\/0002512-200926020-00004","article-title":"Pharmacist-based medication review reduces potential drug-related problems in the elderly: The SMOG controlled trial","volume":"26","author":"Vinks","year":"2009","journal-title":"Drugs Aging"},{"key":"10.3233\/JPD-213021_ref16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12875-016-0577-x","article-title":"Effectiveness of medication review: A systematic review and meta-analysis of randomized controlled trials","volume":"18","author":"Huiskes","year":"2017","journal-title":"BMC Fam Pract"},{"key":"10.3233\/JPD-213021_ref17","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/bcp.12140","article-title":"A systematic review and meta-analysis of pharmacist-led fee-for-services medication review","volume":"77","author":"Hatah","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.3233\/JPD-213021_ref18","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s40273-015-0270-2","article-title":"Cost-utility analysis of a medication review with follow-up service for older adults with polypharmacy in community pharmacies in Spain: The conSIGUE program","volume":"33","author":"J\u00f3dar-S\u00e1nchez","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"10.3233\/JPD-213021_ref19","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/fampra\/cmx007","article-title":"The effectiveness of optimised clinical medication reviews for geriatric patients: Opti-Med a cluster randomised controlled trial","volume":"34","author":"Willeboordse","year":"2017","journal-title":"Fam Pract"},{"key":"10.3233\/JPD-213021_ref21","first-page":"D1772","article-title":"Periodical medication review: Bigger and better?","volume":"161","author":"van Marum","year":"2017","journal-title":"Ned Tijdschr Geneeskd"},{"key":"10.3233\/JPD-213021_ref23","doi-asserted-by":"crossref","first-page":"e1002798","DOI":"10.1371\/journal.pmed.1002798","article-title":"Effects of a clinical medication review focused on personal goals, quality of life, and health problems in older persons with polypharmacy: A randomised controlled trial (DREAMeR-study)","volume":"16","author":"Verdoorn","year":"2019","journal-title":"PLoS Med"},{"key":"10.3233\/JPD-213021_ref24","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/WNF.0000000000000260","article-title":"Effect of pharmacist-led interventions on (non)motor symptoms, medication-related problems, and quality of life in Parkinson disease patients: A pilot study","volume":"41","author":"Stuijt","year":"2018","journal-title":"Clin Neuropharmacol"},{"key":"10.3233\/JPD-213021_ref25","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/ijcp.12439","article-title":"Adherence therapy improves medication adherence and quality of life in people with Parkinson\u2019s disease: A randomised controlled trial","volume":"68","author":"Daley","year":"2014","journal-title":"Int J Clin Pract"},{"key":"10.3233\/JPD-213021_ref26","doi-asserted-by":"crossref","first-page":"100308","DOI":"10.1016\/j.conctc.2018.100308","article-title":"The effect of a structured medication review on quality of life in Parkinson\u2019s disease: The study protocol","volume":"13","author":"Oonk","year":"2018","journal-title":"Contemp Clin Trials Commun"},{"key":"10.3233\/JPD-213021_ref27","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":"Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: A clinico-pathological study of 100 cases","volume":"55","author":"Hughes","year":"1992","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JPD-213021_ref28","first-page":"1093","article-title":"Drug-related problems: Their structure and function","volume":"24","author":"Strand","year":"1990","journal-title":"Ann Pharmacother"},{"key":"10.3233\/JPD-213021_ref29","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12877-017-0621-2","article-title":"What is polypharmacy? A systematic review of definitions","volume":"17","author":"Masnoon","year":"2017","journal-title":"BMC Geriatr"},{"key":"10.3233\/JPD-213021_ref30","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1212\/WNL.55.6.888","article-title":"Progression of Hoehn and Yahr stages in Parkinsonian disorders: A clinicopathologic study","volume":"55","author":"M\u00fcller","year":"2000","journal-title":"Neurology"},{"key":"10.3233\/JPD-213021_ref31","doi-asserted-by":"crossref","first-page":"21122","DOI":"10.1136\/bmjopen-2017-021122","article-title":"The validity of the Rx-Risk Comorbidity Index using medicines mapped to the Anatomical Therapeutic Chemical (ATC) Classification System","volume":"8","author":"Pratt","year":"2018","journal-title":"BMJ Open"},{"key":"10.3233\/JPD-213021_ref32","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/ageing\/26.5.353","article-title":"The Parkinson\u2019s Disease Questionnaire (PDQ-39): Development and validation of a Parkinson\u2019s disease summary index score","volume":"26","author":"Jenkinson","year":"1997","journal-title":"Age Ageing"},{"key":"10.3233\/JPD-213021_ref33","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/ageing\/30.4.299","article-title":"Determining minimally important differences for the PDQ-39 Parkinson\u2019s disease questionnaire","volume":"30","author":"Peto","year":"2001","journal-title":"Age Ageing"},{"key":"10.3233\/JPD-213021_ref34","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1477-7525-3-83","article-title":"The Academic Medical Center Linear Disability Score (ALDS) item bank: Item response theory analysis in a mixed patient population","volume":"3","author":"Holman","year":"2005","journal-title":"Health Qual Life Outcomes"},{"key":"10.3233\/JPD-213021_ref35","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/mds.20844","article-title":"International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson\u2019s disease: The NMSQuest study","volume":"21","author":"Chaudhuri","year":"2006","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-213021_ref36","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: A measure of health status from the EuroQol Group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann Med"},{"key":"10.3233\/JPD-213021_ref37","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jval.2016.01.003","article-title":"Dutch tariff for the five-level version of EQ-5D","volume":"19","author":"Versteegh","year":"2016","journal-title":"Value Heal"},{"key":"10.3233\/JPD-213021_ref38","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.parkreldis.2012.11.018","article-title":"The PDQ-Carer: Development and validation of a summary index score","volume":"19","author":"Morley","year":"2013","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-213021_ref39","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/ageing\/afl055","article-title":"The Parkinson\u2019s Disease Questionnaire (PDQ-39): Evidence for a method of imputing missing data","volume":"35","author":"Jenkinson","year":"2006","journal-title":"Age Ageing"},{"key":"10.3233\/JPD-213021_ref40","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40266-012-0048-6","article-title":"The relationship between the extent of collaboration of general practitioners and pharmacists and the implementation of recommendations arising from medication review: A systematic review","volume":"30","author":"Kwint","year":"2013","journal-title":"Drugs Aging"},{"key":"10.3233\/JPD-213021_ref41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/00019053-200927010-00003","article-title":"Is medication review by primary-care pharmacists for older people cost effective? A narrative review of the literature, focusing on costs and benefits","volume":"27","author":"Zermansky","year":"2009","journal-title":"Pharmacoeconomics"}],"container-title":["Journal of Parkinson's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JPD-213021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:51:16Z","timestamp":1777611076000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JPD-213021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,24]]},"references-count":38,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.3233\/jpd-213021","relation":{},"ISSN":["1877-7171","1877-718X"],"issn-type":[{"value":"1877-7171","type":"print"},{"value":"1877-718X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,24]]}}}